Oura, Tomonori

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial

Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 226

Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes ( SURPASS J‐mono substudy)

Yabe, D., Kawamori, D., Seino, Y., Oura, T., & Takeuchi, M. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 48

Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan

Onishi, Y., Oura, T., Matsui, A., Matsuura, J., & Iwamoto, N. (2017) · Endocrine Journal

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 47

Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes

Onishi, Y., Oura, T., Nishiyama, H., Ohyama, S., Takeuchi, M., & Iwamoto, N. (2016) · Endocrine Journal

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 31